Table 2.

Summary of gemcitabine navitoclax combinations in 27 ovarian cancer cell lines

Cell lineAverage Bliss sumSD Bliss SumAverage combined% inhibitionaSD Combined % inhibitionaAverage % inhibition (3 μmol/L gemcitabine)SD % inhibition (3 μmol/L gemcitabine)Average % inhibition (3 μmol/L navitoclax)SD % inhibition (3 μmol/L navitoclax)Gemcitabine IC50 (nmol/L)SD gemcitabine IC50Navitoclax IC50 (μmol/L)SD navitoclax IC50
EF0277037835.14013.8409.4NANA
Ovcar5627203971.0732.1489.60.020.02NA
OV905356887.0630.55012.10.010.0NA
59M391210776.4308.7155.2NANA
Ovcar838150982.18127.71711.80.0040.00NA
OV56368317920.7772.6311.90.10.1NA
EF021351122873.9444.1426.6NANA
A2780262119990.2902.1117.00.0030.00NA
OAW2824917961.55619.9892.20.90.10.040.0
CA-OV32487875.1775.4173.10.10.1NA
ES2-TO247112882.2681.5169.40.10.0NA
Ovcar42041315813.3293.5184.1NANA
IGROV1197108952.3706.35121.10.10.1NA
HEY1193958512.75914.71510.30.20.0NA
TOV21G188105731.7602.0232.70.30.2NA
OvCA4291568918.0857.267.30.20.1NA
Dor131545957.4904.7695.60.20.00.60.3
COLO704153435621.94220.33325.4NANA
OAW4213469960.8823.1796.70.30.10.50.2
OvCA43212815828.34111.75016.4NANA
Ovcar310316705.84821.6284.4NANA
OvCA4339888914.8729.31617.50.40.3NA
A2780ADR90159791.8702.0103.60.20.0NA
OvCA4207089015.6608.76116.60.30.20.72.2
SKOV330121913.2653.74813.60.70.3NA
TOV112D−3668921.6890.72675.00.20.01.40.6
Fu-Ov-1−58111336.843.4304.8NANA

NOTE: Navitoclax was dosed in a range of 3 μmol/L to 10 nmol/L in 7 threefold dilutions, and gemcitabine was dosed in the range of 3 μmol/L to 0.5 nmol/L in 9 threefold dilutions. Each value reported is the average of at least 3 independent experiments run in quadruplicate. IC50 values and Bliss scores were measured using CellTiter-Glo.

a% Inhibition at 3 μmol/L gemcitabine and 3 μmol/L navitoclax.